SPONSOR
Fujian Medical University Union Hospital
Total Trials
2
Recruiting
2
Phases
Phase 2
Fujian Medical University Union Hospital is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Muscle Invasive Bladder Cancer (MIBC), PARKINSON DISEASE (Disorder).
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Fujian Medical University Union Hospital
How many clinical trials has Fujian Medical University Union Hospital sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Fujian Medical University Union Hospital, of which 2 are actively recruiting participants. These trials cover conditions including Muscle Invasive Bladder Cancer (MIBC), PARKINSON DISEASE (Disorder). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Fujian Medical University Union Hospital research focus on?
Fujian Medical University Union Hospital clinical trials span Muscle Invasive Bladder Cancer (MIBC), PARKINSON DISEASE (Disorder). The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Fujian Medical University Union Hospital clinical trial?
To participate in a Fujian Medical University Union Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fujian Medical University Union Hospital trials with current recruitment status updated daily.
Clinical Trials by Fujian Medical University Union Hospital
NCT07296705 Phase 2
Recruiting
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Muscle Invasive Bladder Cancer (MIBC)
NCT07679256
Recruiting
Integrated Digital and Neurogenic Exosome Biomarkers for Early Diagnosis of Parkinson's Disease: Development and Application
PARKINSON DISEASE (Disorder)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology